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Conclusion: We have developed a novel method to simulate a 
model based virtual RS that is a useful tool to identify 
patients with a potentially high benefit of a RS implantation. 
The volume of the virtual RS can be estimated through the 
use of different deformation fields. In future, a dose 
comparison study is necessary to extend into a full decision 
support system using the virtual RS approach. 
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Purpose or Objective: The escalation dose in the treatment 
of prostate cancer with external beam radiation therapy has 
proved the winning way in the biochemical control of the 
tumor. But the dose escalation to the whole prostate gland, 
which is considered as clinical target volume in external 
beam radiotherapy, is limited by the tolerance of the 
surrounding tissue. We have compared the toxicity profiles 
between patients treated with moderate hypofractionated 3-
dimensional conformal radiotherapy (3D-CRT) collated with 
volumetric-modulated arc therapy (VMAT), both with image-
guided radiotherapy (IGRT) by implanted fiducial markers in 
prostate gland (FMs) . 
 
Material and Methods: Between 2009 and 2011, 41 patients 
with prostate cancer were treated with 3DCRT-IG to a dose 
of 70 Gy 2.5 Gy/fr with daily online correction of the target 
position based on MV/MV. This group of patients was 
compared with a similar cohort of 39 patients who were 
treated between 2012 and 2014 with VMAT-IG to the same 
prescription dose with daily online correction of the target 
position based on MV/KV imaging. The clinical characteristics 
of these two patient populations are shown in Table 1. 
Radiation Therapy Oncology Group/European Organization for 
Research and Treatment of Cancer late morbidity 
RTOG/EORTC scores were used for acute and late effects. 
The median follow-up time was 3 years (range, 1-6 years). 
The rectal and bladder dose parameters were also included in 




Results: The rectal acute and late toxicity was low for both 
treatment groups and no significant reduction was observed 
for VMAT-IG patients compared with the 3DCRT-IG patients (P 
= 0.33). The likelihood acute genitourinary toxicity for the 
VMAT-IG and 3DCRT-IG cohorts were 14.5% and 18.0%, 
respectively (p = 0.61). Only for grade ≥ 2 acute 
genitourinary toxicity, the analyses showed a trend better 
but non significative result on behalf of VMAT-IG (P=0,09). 
Finally, no significant correlation was observed between the 
dose parameters and genito-urinary and rectal late toxicity 
The PSA relapse-free survival in according to Phoenix criteria 
(nadir plus 2 ng/ml) for 3D-CRT and VMAT were similar (98% 
vs. 96%; p = 0.34). 
 
Conclusion: Moderate hypofractionated IGRT is associated 
with a lower rate of genito-urinary and rectal toxicity for 
both treatment 3D-CRT and VMAT. These data suggest that, 
the placement of fiducial markers and daily online correction 
of target positioning may represent the preferred mode of 
external-beam radiotherapy delivery for the patients treated 
by definitive radiotherapy. 
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